Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ladarixin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 known ✓ | P25025 | 4/20 | 1.00 |
| ▸ | CXCR1 known ✓ | P25024 | 3/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ladarixin SCHEMBL253446 | 1.00 | CXCR2 (1.00) | CXCR2CXCR1THRBAKR1C3AKR1C2 | |
| Ladarixin SCHEMBL6371049 | 0.96 | CXCR2 (0.92) | CXCR2CXCR1THRBAKR1C3AKR1C2 | |
| SCHEMBL14175172 | 0.87 | CXCR2 (0.78) | CXCR2CXCR1AKR1C3AKR1C2CA12 | |
| SCHEMBL28803928 | 0.86 | CXCR2 (0.76) | CXCR2CXCR1AKR1C3AKR1C2CA12 | |
| SCHEMBL251658 | 0.86 | CXCR2 (0.75) | CXCR2CXCR1GPR88CA12CA1 | |
| SCHEMBL250803 | 0.86 | CXCR2 (0.75) | CXCR2CXCR1GPR88CA12CA1 | |
| SCHEMBL27219472 | 0.84 | CXCR2 (0.73) | CXCR2CXCR1GPR88 | |
| SCHEMBL27219474 | 0.84 | CXCR2 (0.73) | CXCR2CXCR1GPR88 | |
| SCHEMBL27925084 | 0.83 | CXCR2 (0.70) | CXCR2CXCR1AKR1C3AKR1C2GPR88 | |
| SCHEMBL12239572 | 0.82 | CXCR2 (0.70) | CXCR2CXCR1THRBAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2025151629-A2 | METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH INFLAMMATION, PAIN AND/OR LESIONS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-07-17 | — | — | WO | claimed |
| US-20250161248-A1 | Treating Chronic Myelomonocytic Leukemia with CXCL8 Receptor Inhibitors | INSTITUT GUSTAVE ROUSSY (FR) | 2025-05-22 | — | — | US | claimed |
| EP-3773563-B1 | PRODRUGS OF FUSED-BICYCLIC C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2024-10-16 | — | — | EP | claimed |
| WO-2024146918-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | DOMPE' FARMACEUTICI SPA (IT) | 2024-07-11 | — | — | WO | claimed |
| EP-4397305-A1 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompe' Farmaceutici S.P.A. (IT) | 2024-07-10 | — | — | EP | claimed |
| US-20240115527-A1 | CXCR1/CXCR2 INHIBITORS FOR USE IN TREATING MYELOFIBROSIS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2024-04-11 | — | — | US | claimed |
| EP-3728203-B1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX INC (US) | 2024-03-13 | — | — | EP | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20230310479-A1 | LOW DOSE ADJUVANT EPIGENETIC CANCER THERAPY | UNIV JOHNS HOPKINS (US) | 2023-10-05 | — | — | US | claimed |
| WO-2018127469-A1 | IL-8 INIHIBITORS FOR USE IN THE TREATMENT OF SOME UROLOGICAL DISORDERS | DOMPE' FARMACEUTICI S.P.A. (IT) | 2018-07-12 | — | — | WO | claimed |
| EP-3342407-A1 | IL-8 INIHIBITORS FOR USE IN THE TREATMENT OF SOME UROLOGICAL DISORDERS | Dompé farmaceutici S.p.A. (IT) | 2018-07-04 | — | — | EP | claimed |
| EP-3117835-A1 | IL-8 INHIBITORS FOR USE IN THE TREATMENT OF CERTAIN UROLOGICAL DISORDERS | Dompé farmaceutici s.p.a. (IT) | 2017-01-18 | — | — | EP | claimed |
| US-8293788-B2 | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2012-10-23 | — | — | US | claimed |
| US-20120004264-A1 | 2-PHENYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPÉ PHA.R.MA S.P.A. (IT) | 2012-01-05 | — | — | US | claimed |
| US-8039656-B2 | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2011-10-18 | — | — | US | claimed |
| EP-1776336-B1 | 2-PHENYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-09-30 | — | — | EP | claimed |
| US-20090203740-A1 | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them | DOMPE' PHA.R.MA S.P.A (IT) | 2009-08-13 | — | — | US | claimed |
| EP-1776336-A2 | 2-PHENYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2007-04-25 | — | — | EP | claimed |
| WO-2005090295-A2 | 2-PHENYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA S.P.A. (IT) | 2005-09-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203740-A1 | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them | CXCR2, CXCR3, MMP8 | CXCR2 1/4885CXCR1 4/4885THRB 3677/4885 |
| US-20240115527-A1 | CXCR1/CXCR2 INHIBITORS FOR USE IN TREATING MYELOFIBROSIS | CXCR1, CXCR2, CXCL8 | CXCR2 2/4885CXCR1 1/4885THRB 2036/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | CXCR2 1756/4885CXCR1 3248/4885THRB 330/4885 |
| US-20120004264-A1 | 2-PHENYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CXCR2, CXCR3, MMP8 | CXCR2 1/4885CXCR1 4/4885THRB 3677/4885 |
| US-20250161248-A1 | Treating Chronic Myelomonocytic Leukemia with CXCL8 Receptor Inhibitors | CXCL8, CCR8, CSF3R | CXCR2 5/4885CXCR1 15/4885THRB 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.